As with the drug-addicted cell line in our model of trametinib resistance, amplification of mutant KRAS in response to AMG-510 may render these tumor cells sensitive to hyperactivation of MAPK signaling if AMG-510 is withdrawn. Here, KRAS is linked to neoplasm.